What do systematic reviews say?

Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

Total number of serious adverse events not measured · patients with osteoarthritis

Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma

Number of participants experiencing any serious adverse events · patients with osteoarthritis

Number of participants experiencing any serious adverse events · patients with osteoarthritis

Number of participants experiencing 1 or more serious adverse events at the end of the intervention period · cognitively healthy people in late life

Number of participants experiencing 1 or more serious adverse events at the end of the intervention period · cognitively healthy people in late life

There was no evidence of differences in the number of serious adverse events for any of the comparisons Quality of evidence = very low1,2,3. · people undergoing liver resection

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease